<DOC>
	<DOCNO>NCT02145741</DOCNO>
	<brief_summary>This open-label dose escalation phase I trial , 1280.15 , first administration BI 836845 Japanese patient various type advance solid tumour . The rationale behind study identify maximum tolerate dose ( MTD ) BI 836845 Japanese patient advance solid tumour weekly intravenous administration .</brief_summary>
	<brief_title>Weekly Intravenous Administrations BI 836845 Japanese Patients With Advanced Solid Tumours</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : Patients meet follow inclusion criterion judgment investigator eligible receive study treatment : 1 . Patients cytologically histologically confirm solid tumour refractory standard therapy , standard therapy proven efficacy exist , amenable establish treatment option 2 . Age &gt; =20 year old 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 4 . Written inform consent consistent Good Clinical Practice ( GCP ) guideline Exclusion criterion : Patients apply follow exclusion criterion judgment investigator eligible receive study treatment : 1 . Active infectious disease incompatible study treatment 2 . Patients sufficient major organ function meet follow test result screen period Cardiac leave ventricular function rest ejection fraction &lt; =50 % determine echocardiography ( ECHO ) multiplegated acquisition scan ( MUGA ) Absolute neutrophil count &lt; 1500/µL Platelets &lt; 100 000/µL Total bilirubin &gt; 1.5 × upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 2.5 × ULN ( case know liver metastasis , AST and/or ALT &gt; 5 × ULN ) Creatinine &gt; 1.5 × ULN Haemoglobin &lt; 9 g/dL HbA1c &gt; =8 % fast glucose &gt; 8.9 mmol/L ( &gt; 160 mg/dL ) 3 . Serious illness concomitant nononcological disease include severe , acute , chronic medical psychiatric condition , laboratory abnormality may compromise safety patient study , affect patient 's ability complete study , interfere interpretation study result consider investigator incompatible study treatment 4 . History thrombosis ( except tumour invade great vessel ) within 1 year start study treatment concurrent anticoagulation require 5 . Patients recover therapyrelated toxicity previous chemotherapy , hormonal therapy , immunotherapy , moleculartargeted therapy , radiotherapy Common Terminology Criteria Adverse Events ( CTCAE ) grade &lt; =1 6 . Patients recover previous surgery major surgery within last 4 week start study treatment 7 . Patients untreated symptomatic brain metastasis . 8 . Patients treat follow within 4 week start study treatment : chemotherapy , immunotherapy , radiotherapy ( within 2 week start study treatment local palliative radiotherapy treatment brain metastasis extremity ) , biological therapy , moleculartargeted therapy , hormonal therapy breast cancer within 2 week start study treatment , treatment investigational drug . 9 . Patients used investigational drug within 4 week start study treatment plan concomitantly use trial . 10 . Patients unable comply clinical trial protocol ( CTP )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>